Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

June 1, 2025

Study Completion Date

September 1, 2035

Conditions
Gastric CancerPancreatic Cancer
Interventions
BIOLOGICAL

CT041

treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion

Trial Locations (16)

10029

The Mount Sinai Hospital, New York

10065

Memorial Sloan Kettering Cancer Center, New York

11042

Northwell Cancer Institute, New Hyde Park

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University, Columbus

48201

Karmanos Cancer Center, Detroit

53226

Froedtert Hospital and the Medical College of Wisconsin, Milwaukee

55905

Mayo Cancer Hospital, Rochester

66160

University of Kansas Cancer Center, Kansas City

75246

TX Oncology-Baylor Charles Sammons Cancer Center, Dallas

77030

MD Anderson Cancer Center, Houston

90089

University of Southern California, Los Angeles

91010

City of Hope, Duarte

92093

UCSD, San Diego

94143

UCSF, San Francisco

M5GH 2C1

Princess Margaret Hospital, Toronto

Sponsors
All Listed Sponsors
lead

CARsgen Therapeutics Co., Ltd.

INDUSTRY